Devicemaker targets athletes with concussion-detecting tech; Small-time device firms face tough path;

@FierceMedDev: While purchasers praise the FDA's device ID plan, members of the industry remain wary. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: Roche gets its second FDA diagnostic approval this week, this time for a virus test. Story | Follow @DamianFierce

> Devicemaker Cenora is developing a mobile medical device designed to detect concussions, hoping to get 510(k) clearance and use the tech on athletes. News

> Crain's takes a look at the rocky road small devicemakers face when trying to get their techs on the market. Article

> Vascular Flow Technologies is touting positive first-in-man trial results for Spiral Flow, an investigative bypass graft designed to treat peripheral artery disease. Release

> The U.K.'s Deltex Medical has seen a sales boost for its CardioQ surgical probe, thanks to a NICE recommendation and demand from the National Health Service. Story

Biotech News

 @FierceBiotech: Pfizer inks licensing deal with Russia's SatRx for diabetes drug. Release | Follow @FierceBiotech

 @JohnCFierce: So K-V says that if the FDA doesn't ride to its rescue on Makena comp, it's going bankrupt in a few months. Buh-bye. More | Follow @JohnCFierce

 @RyanMFierce: Interesting biotech startup opportunity: nanoparticles that reduce amount of active drug needed combat clots. More | Follow @RyanMFierce

> Forest Labs pressured to pull trigger on M&A after patent expires on Lexapro. Story

> Struggling K-V Pharma brings lawsuit against FDA. More

> Biotech startup ADCT and U.K. researchers conspire to arm anti-cancer 'warheads'. News

Pharma News

 @FiercePharma: Top EMA lawyer jumps ship for SIdley Austin, private firm repping pharma companies. Agency investigates--FT. More | Follow @FiercePharma

> Pfizer trimming health claims on Centrum. Story

> NICE turns down Avastin for breast cancer. News

> K-V says it will go bankrupt without FDA intervention. Article

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.